For this study, we hypothesized that colon carcinoma cells form TNTs at rates that vary based on KRAS status (wild type vs. mutant) and site of origin (i.e., cells derived from a primary CRC tumor vs. metastatic CRC tumors) (Table 1). The gene discussed is KRAS; the disease is colon carcinoma.